An Analysis of Dosage Volume for Halfway Doses in the Victoza Pen

King A Wolfe G . Accuracy of Dosage Volume for Halfway Doses in the Victoza Pen. J Diabetes Sci Technol. 2011; (5) 6: 1623–4.

Marre M Shaw J Brändle M Bebakar WM Kamaruddin NA Strand J Zdravkovic M Le Thi TD Colagiuri S ; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26 (3): 268–78.

Nauck M Frid A Hermansen K Shah NS Tankova T Mitha IH Zdravkovic M Düring M Matthews DR ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32 (1): 84–90.

Garber A Henry R Ratner R Garcia-Hernandez PA Rodriguez-Pattzi H Olvera-Alvarez I Hale PM Zdravkovic M Bode B ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373 (9662): 473–81.

Zinman B Gerich J Buse JB Lewin A Schwartz S Raskin P Hale PM Zdravkovic M Blonde L ; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32 (7): 1224–30.

Russell-Jones D Vaag A Schmitz O Sethi BK Lalic N Antic S Zdravkovic M Ravn GM Simó R ; Liraglutide. Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009;52 (10): 2046–55.

Buse JB Rosenstock J Sesti G Schmidt WE Montanya E Brett JH Zychma M Blonde L ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374 (9683): 39–47.

Vilsbøll T Zdravkovic M Le-Thi T Krarup T Schmitz O Courrèges J P Verhoeven R Bugánová I Madsbad S . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30 (6): 1608–10.